Progress of Sequences and Results
| Parameter | Available data (n) | PRRT1–Eve2 | Eve1–PRRT2 | P |
|---|---|---|---|---|
| No. of patients | 24 | 60 | ||
| First line | PRRT1 | Eve1 | ||
| Time of treatment (mo) | 84 | 5.5 (4.5–6.2) | 9.5 (2.4–18.7) | <0.001 |
| Concurrent SSAs | 84 | 16 (66.7) | 31 (51.7) | 0.21 |
| Dose or activity adjustment during treatment | 82 | 2 (8.7) | 19 (32.2) | 0.03 |
| Everolimus discontinuation or delay of PRRT administration | 84 | 1 (4.2) | 60 (100) | <0.001 |
| Reason for treatment discontinuation | 84 | <0.001 | ||
| Scheduled | 23 (95.8) | 1 (1.7) | ||
| Disease progression | 1 (4.2) | 24 (40.0) | ||
| Toxicity | 0 (0) | 35 (58.3) | ||
| Objective response | 83 | 6 (25.0) | 5 (8.5) | 0.04 |
| PFS (mo)* | 83 | 16.4 (9.2–23.6) | 18.2 (14–22.4) | 0.90 |
| Time between 2 treatments (mo) | 83 | 14.0 (8.4–21.7) | 7.3 (2.3–21.5) | 0.22 |
| Locoregional treatment given between 2 treatments | 83 | 7 (29.1) | 22 (36.7) | 0.43 |
| Second line | Eve2 | PRRT2 | ||
| Time of treatment (mo) | 84 | 3.7 (2.1–7.5) | 5.5 (4.7–5.9) | <0.001 |
| Concurrent SSAs | 83 | 16 (66.7) | 38 (64.4) | 0.84 |
| Dose or activity adjustment during treatment | 83 | 16 (66.7) | 7 (11.9) | <0.001 |
| Everolimus discontinuation or delay of PRRT administration | 82 | 19 (82.6) | 11 (19) | <0.001 |
| Reason for treatment discontinuation | 82 | <0.001 | ||
| Scheduled | 2 (9.5) | 47 (81) | ||
| Disease progression | 9 (42.9) | 2 (3.4) | ||
| Toxicity | 10 (47.6) | 8 (13.8) | ||
| Patient’s choice | 0 (0) | 1 (1.7) | ||
| Objective response | 81 | 0 (0) | 13 (22.4) | 0.01 |
| PFS (mo) | 80 | 6.8 (3.8–9.8) | 26.4 (22.6–30.2) | 0.005 |
↵* PFS data are median and 95% CI.
Unless indicated otherwise, qualitative data are number and percentage and continuous data are median and IQR.